Current allosteric MEK inhibitors are clinically approved for treatment of BRAFV600E mutant cancer either alone or in combination with RAF inhibitors.440 However, MEK inhibitors have only exhibited modest efficacy against RAS mutant tumors in clinical trials, with NRAS mutant melanoma being the only subtype showing responsiveness to MEK inhibition. This evidence concerns the gene MAP2K7 and cancer.